Summary of Study ST003030

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001883. The data can be accessed directly via it's Project DOI: 10.21228/M89X4H This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST003030
Study TitleA small molecule macrophage migration inhibitory factor agonist ameliorates age-related myocardial intolerance to ischemia-reperfusion insults via metabolic regulation - Part 2
Study SummaryMacrophage migration inhibitory factor (MIF) is an innate cytokine that regulates both inflammatory and homeostatic responses. MIF is expressed by cardiomyocytes, where it exerts a protective action against ischemia-reperfusion (I/R) injury by activating AMP-activated protein kinase (AMPK). This effect is attenuated in the senescent heart due to an intrinsic, age-related reduction in MIF expression. We hypothesized that treating the aged heart with the small molecule MIF agonist (MIF20) can reinforce protective MIF signaling in cardiomyocytes, leading to a beneficial effect against I/R stress. The administration of MIF20 at the onset of reperfusion was found to not only decrease myocardial infarct size but also preserves systolic function in the aged heart. Protection from I/R injury was reduced in mice with cardiomyocyte-specific Mif deletion, consistent with the mechanism of action of MIF20 to allosterically increase MIF affinity for its cognate receptor CD74. We further found MIF20 to contribute to the maintenance of mitochondrial fitness and to preserve the contractile properties of aged cardiomyocytes under hypoxia/reoxygenation. MIF20 augments protective metabolic responses by reducing the NADH/NAD ratio, leading to a decrease in the accumulation of reactive oxygen species (ROS) in the aged myocardium under I/R stress. We also identify alterations in the expression levels of the downstream effectors PDK4 and LCAD, which participate in the remodeling of the cardiac metabolic profile. Data from this study demonstrates that pharmacologic augmentation of MIF signaling provides beneficial homeostatic actions on senescent myocardium under I/R stress.
Institute
University of Mississippi Medical Center
Last NameLi
First NameJi
Address2500 N State St, Jackson, MS 39216-4505
Emailjli3@umc.edu
Phone6018158995
Submit Date2023-12-18
Analysis Type DetailLC-MS
Release Date2024-06-18
Release Version1
Ji Li Ji Li
https://dx.doi.org/10.21228/M89X4H
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001883
Project DOI:doi: 10.21228/M89X4H
Project Title:A small molecule macrophage migration inhibitory factor agonist ameliorates age-related myocardial intolerance to ischemia-reperfusion insults via metabolic regulation
Project Summary:Macrophage migration inhibitory factor (MIF) is an innate cytokine that regulates both inflammatory and homeostatic responses. MIF is expressed by cardiomyocytes, where it exerts a protective action against ischemia-reperfusion (I/R) injury by activating AMP-activated protein kinase (AMPK). This effect is attenuated in the senescent heart due to an intrinsic, age-related reduction in MIF expression. We hypothesized that treating the aged heart with the small molecule MIF agonist (MIF20) can reinforce protective MIF signaling in cardiomyocytes, leading to a beneficial effect against I/R stress. The administration of MIF20 at the onset of reperfusion was found to not only decrease myocardial infarct size but also preserves systolic function in the aged heart. Protection from I/R injury was reduced in mice with cardiomyocyte-specific Mif deletion, consistent with the mechanism of action of MIF20 to allosterically increase MIF affinity for its cognate receptor CD74. We further found MIF20 to contribute to the maintenance of mitochondrial fitness and to preserve the contractile properties of aged cardiomyocytes under hypoxia/reoxygenation. MIF20 augments protective metabolic responses by reducing the NADH/NAD ratio, leading to a decrease in the accumulation of reactive oxygen species (ROS) in the aged myocardium under I/R stress. We also identify alterations in the expression levels of the downstream effectors PDK4 and LCAD, which participate in the remodeling of the cardiac metabolic profile. Data from this study demonstrates that pharmacologic augmentation of MIF signaling provides beneficial homeostatic actions on senescent myocardium under I/R stress.
Institute:University of Mississippi Medical Center
Last Name:Li
First Name:Ji
Address:2500 N State St, Jackson, MS 39216-4505
Email:jli3@umc.edu
Phone:6018158995

Subject:

Subject ID:SU003144
Subject Type:Mammal
Subject Species:Mus musculus
Taxonomy ID:10090

Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Genotype Treatment
SA3280937_20Aged-wildtype Aged I/R
SA3280947_19Aged-wildtype Aged I/R
SA3280957_21Aged-wildtype Aged I/R
SA3280968_22Aged-wildtype Aged I/R +MIF20
SA3280978_24Aged-wildtype Aged I/R +MIF20
SA3280988_23Aged-wildtype Aged I/R +MIF20
SA3280995_15Aged-wildtype Sham aged
SA3281005_14Aged-wildtype Sham aged
SA3281015_13Aged-wildtype Sham aged
SA3281026_17Aged-wildtype Sham aged+MIF20
SA3281036_16Aged-wildtype Sham aged+MIF20
SA3281046_18Aged-wildtype Sham aged+MIF20
SA3281051_3Young-wildtype Sham young
SA3281061_1Young-wildtype Sham young
SA3281071_2Young-wildtype Sham young
SA3281082_5Young-wildtype Sham young+MIF20
SA3281092_4Young-wildtype Sham young+MIF20
SA3281102_6Young-wildtype Sham young+MIF20
SA3281113_8Young-wildtype Young I/R
SA3281123_7Young-wildtype Young I/R
SA3281133_9Young-wildtype Young I/R
SA3281144_12Young-wildtype Young I/R+MIF20
SA3281154_11Young-wildtype Young I/R+MIF20
SA3281164_10Young-wildtype Young I/R+MIF20
Showing results 1 to 24 of 24

Collection:

Collection ID:CO003137
Collection Summary:The sample collection method was as follows: All mouse groups underwent anesthesia with 2%-3% isoflurane and 100% O2. The mouse hearts were excised and rinsed in ice-cold PBS. Both atriums were removed; only the left ventricular myocardium, including the infarct area, was collected and was quickly frozen by using liquid nitrogen. Samples were preserved below -80 °C and were sent out for metabolomic analysis.
Sample Type:Heart

Treatment:

Treatment ID:TR003153
Treatment Summary:Sham young;Sham young+MIF20;Young I/R;Young I/R+MIF20;Sham aged;Sham aged+MIF20;Aged I/R;Aged I/R +MIF20

Sample Preparation:

Sampleprep ID:SP003150
Sampleprep Summary:The metabolomic sample preparation method was: The tissue samples were ground into a homogenous powder with a Retsch Cryomill (Retsch-Allee, Haan, Germany). 45 – 80 mg of the pulverized sample was weighed and stored in the -80 oC freezer prior to extraction. Samples were allowed to thaw at 4 °C for 30 min before adding 1.5 mL of 20:40:40 water/methanol/acetonitrile with 0.1 M formic acid for metabolites extraction. The samples were vortexed and centrifuged and the supernatants were isolated and dried completely under nitrogen. The dried samples were resuspended in 300 µL water and an aliquot were transferred to autosampler vials for UHPLC-HRMS analysis. Mass analysis was carried out at the University of Tennessee Biological and Small Molecule Mass Spectrometry Core (RRID: SCR_021368) using an UltiMate 3000 liquid chromatography system (Dionex, Sunnyvale, CA, USA) coupled to an Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).

Combined analysis:

Analysis ID AN004967
Analysis type MS
Chromatography type Reversed phase
Chromatography system Thermo Dionex Ultimate 3000
Column Phenomenex Synergi Hydro-RP (100 x 2mm,2.5um)
MS Type ESI
MS instrument type Orbitrap
MS instrument name Thermo Exactive Plus Orbitrap
Ion Mode NEGATIVE
Units Peak area

Chromatography:

Chromatography ID:CH003749
Chromatography Summary:Mass analysis was carried out at the University of Tennessee Biological and Small Molecule Mass Spectrometry Core (RRID: SCR_021368) using an UltiMate 3000 liquid chromatography system (Dionex, Sunnyvale, CA, USA) coupled to an Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). Metabolites were separated using a Synergi Hydro RP column (2.5 μm, 100 × 2.0 mm; Phenomenex, Torrance, CA, USA) using a reversed phase ion pairing chromatographic method. This method uses a tributylamine ion pairing reagent with a water: methanol solvent gradient elution within a 25-minute duration as reported previously (Bazurto et al, 2018: Bazurto JV, Dearth SP, Tague ED, Campagna SR, Downs DM. Untargeted metabolomics confirms and extends the understanding of the impact of aminoimidazole carboxamide ribotide (AICAR) in the metabolic network of Salmonella enterica. Microb Cell. 2017 Nov 22;5(2):74-87. doi: 10.15698/mic2018.02.613. PMID: 29417056; PMCID: PMC5798407.).
Instrument Name:Thermo Dionex Ultimate 3000
Column Name:Phenomenex Synergi Hydro-RP (100 x 2mm,2.5um)
Column Temperature:25
Flow Gradient:0 to 5 min 0% B, from 5 to 13 min 20% B, from 13 to 15.5 min 55% B, from 15.5 to 19 min 95% B, and from 19 to 25 min 0% B
Flow Rate:200 µL/min
Solvent A:97:3 LCMS grade water : methanol, 11 mM tributylamine, 15 mM acetic acid.
Solvent B:LCMS grade methanol
Chromatography Type:Reversed phase

MS:

MS ID:MS004707
Analysis ID:AN004967
Instrument Name:Thermo Exactive Plus Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Mass analysis was carried out at the University of Tennessee Biological and Small Molecule Mass Spectrometry Core (RRID: SCR_021368) using an UltiMate 3000 liquid chromatography system (Dionex, Sunnyvale, CA, USA) coupled to an Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). Metabolites were separated using a Synergi Hydro RP column (2.5 μm, 100 × 2.0 mm; Phenomenex, Torrance, CA, USA) using a reversed phase ion pairing chromatographic method. This method uses a tributylamine ion pairing reagent with a water: methanol solvent gradient elution within a 25-minute duration as reported previously (Bazurto et al., 2018). All solvents used were LC-MS grade. The chromatographic gradient was from 0 to 5 min 0% B, from 5 to 13 min 20% B, from 13 to 15.5 min 55% B, from 15.5 to 19 min 95% B, and from 19 to 25 min 0% B. (ref to paper: (Bazurto et al, 2018)) The separated metabolites were ionized using electrospray ionization with negative polarity and the full scan mass analysis was performed with a resolution of 140,000 as previously reported. The Xcalibur (RAW) files generated from the UPLC-HRMS analysis were converted to the mzML format using the msconvert software to enable data centroiding. Metabolomic Analysis and Visualization Engine (MAVEN) was used to integrate the peak areas from the extracted ion chromatograms (EIC). Prior to identification and integration, MAVEN was used to perform a nonlinear retention time correction across all samples. Metabolites were identified by comparing chromatographic retention time and exact masses within ± 5 ppm mass tolerance to an in-house standard library. Identifications were validated using the natural abundance of isotopes in the compound. The integrated peak areas were used for further statistical and biological analysis. Unidentified spectral features were annotated and analyzed using online LC-MS raw data spectra processing features in MetaboAnalyst 5.0.
Ion Mode:NEGATIVE
  logo